146 related articles for article (PubMed ID: 8258997)
61. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X; Fenaux P; Dombret H; Delair S; Dreyfus F; Tilly H; Vekhoff A; Cony-Makhoul P; Leblond V; Troussard X; Cordonnier C; de Revel T; Simon M; Nicolini F; Stoppa AM; Janvier M; Bordessoule D; Rousselot P; Ffrench M; Marie JP; Archimbaud E
Leukemia; 1999 Aug; 13(8):1214-20. PubMed ID: 10450749
[TBL] [Abstract][Full Text] [Related]
62. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
63. Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17-1A against human colorectal carcinoma cells: enhancement with interferon gamma.
Takamuku K; Baba K; Arinaga S; Li J; Mori M; Akiyoshi T
Cancer Immunol Immunother; 1996 Dec; 43(4):220-5. PubMed ID: 9003467
[TBL] [Abstract][Full Text] [Related]
64. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease.
Cook AD; Braine EL; Campbell IK; Rich MJ; Hamilton JA
Arthritis Res; 2001; 3(5):293-8. PubMed ID: 11549370
[TBL] [Abstract][Full Text] [Related]
65. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
66. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
[TBL] [Abstract][Full Text] [Related]
67. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
[TBL] [Abstract][Full Text] [Related]
68. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
[TBL] [Abstract][Full Text] [Related]
69. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF).
Economopoulos T; Papageorgiou E; Stathakis N; Constantinidou M; Parharidou A; Kostourou A; Dervenoulas J; Raptis S
Leuk Res; 1996 May; 20(5):385-90. PubMed ID: 8683977
[TBL] [Abstract][Full Text] [Related]
70. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO
Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099
[TBL] [Abstract][Full Text] [Related]
71. OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.
Platzer E; Rubin BY; Lu L; Welte K; Broxmeyer HE; Moore MA
J Immunol; 1985 Jan; 134(1):265-71. PubMed ID: 3917276
[TBL] [Abstract][Full Text] [Related]
72. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
73. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
74. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.
Shea TC; Mason JR; Storniolo AM; Newton B; Breslin M; Mullen M; Ward DM; Miller L; Christian M; Taetle R
J Clin Oncol; 1992 Mar; 10(3):464-73. PubMed ID: 1740685
[TBL] [Abstract][Full Text] [Related]
75. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects.
Tempero MA; Sivinski C; Steplewski Z; Harvey E; Klassen L; Kay HD
J Clin Oncol; 1990 Dec; 8(12):2019-26. PubMed ID: 2121912
[TBL] [Abstract][Full Text] [Related]
76. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
77. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
[TBL] [Abstract][Full Text] [Related]
78. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer.
Dai S; Wei D; Wu Z; Zhou X; Wei X; Huang H; Li G
Mol Ther; 2008 Apr; 16(4):782-90. PubMed ID: 18362931
[TBL] [Abstract][Full Text] [Related]
79. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?
Gires O; Pan M; Schinke H; Canis M; Baeuerle PA
Cancer Metastasis Rev; 2020 Sep; 39(3):969-987. PubMed ID: 32507912
[TBL] [Abstract][Full Text] [Related]
80. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
Niedzwiecki D; Bertagnolli MM; Warren RS; Compton CC; Kemeny NE; Benson AB; Eckhardt SG; Alberts S; Porjosh GN; Kerr DJ; Fields A; Rougier P; Pipas JM; Schwartz JH; Atkins J; O'Rourke M; Perry MC; Goldberg RM; Mayer RJ; Colacchio TA
J Clin Oncol; 2011 Aug; 29(23):3146-52. PubMed ID: 21747085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
